Thermo Fisher Scientific agreed to amass Solventum’s purification and filtration (PF) enterprise for about $4.1 billion in money. The PF enterprise gives purification and filtration applied sciences used within the manufacturing of biologics in addition to in medical applied sciences and industrial functions. The Solventum enterprise operates globally with websites throughout the Americas, Europe, the Center East, Africa, and the Asia-Pacific area, and has roughly 2,500 colleagues. In 2024, Solventum’s PF enterprise generated roughly $1 billion in income.
Solventum’s PF enterprise is extremely complementary to Thermo Fisher’s bioproduction enterprise, in keeping with Marc N. Casper, chairman, president, and CEO of Thermo Fisher. Thermo Fisher has a portfolio of choices in cell tradition media and single-use applied sciences and Solventum’s filtration portfolio broadens Thermo Fisher’s capabilities within the improvement and manufacturing of biologics, spanning upstream and downstream workflows, stated Casper.
“The addition of Solventum’s enterprise is an excellent strategic match with our firm and can create important worth for our clients and shareholders,” added Casper. “Solventum’s portfolio of options will likely be valued by our clients, and additional display our disciplined capital deployment technique which has a superb observe document of making shareholder worth.
“Because the trusted associate to our clients, Solventum’s PF enterprise will develop and add differentiated capabilities to our bioprocessing portfolio to raised serve our clients on this quickly rising market.”
The transaction is predicted to be accomplished by the tip of 2025 and is topic to customary closing circumstances and regulatory approvals. As soon as the transaction closes, Solventum’s PF enterprise will turn into a part of Thermo Fisher’s Life Sciences Options phase.
